Lupus nephritis is a major manifestation of systemic lupus erythematosus. Treatment with such immunosuppressive agents as corticosteroids or cyclophosphamide can decrease the progression of lupus nephritis; however, these agents have potentially severe adverse reactions. Therefore, the development of new drugs with fewer side effects is needed. Here, we report 2 patients with lupus that were treated successfully with retinoids. Initially, both patients were treated with 60 mg/d of prednisolone. However, nephrotic syndrome was not improved. Subsequently, treatment with 10 mg/d of all-trans-retinoic acid was started orally and elicited a good response, showing a decrease in proteinuria. Although additional controlled clinical studies are needed to confirm these findings, we suggest that therapy using retinoids may represent a novel approach to the treatment of patients with lupus nephritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.ajkd.2009.06.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis.
J Clin Med
January 2025
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus, affecting roughly 40% of all lupus patients. With the introduction of cyclophosphamide and mycophenolate mofetil, outcomes have dramatically improved. However, 10% of patients still progress towards end-stage kidney disease, which carries an elevated mortality rate.
View Article and Find Full Text PDFSafety Profile of SARS-CoV-2 Vaccination in Patients with Lupus Nephritis: A Retrospective Study.
J Clin Med
January 2025
Division of Nephrology, 2nd Department of Internal Medicine, Attikon University Hospital, School of Health Sciences, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Vaccination against SARS-CoV-2 has been vital in alleviating the spread of the recent pandemic. We aimed to estimate the frequency and type of adverse events related to SARS-CoV-2 vaccine in patients with lupus nephritis (LN), and assess its impact, if any, on the risk of subsequent reactivation of nephritis. This was a retrospective, multicenter study which included patients with biopsy-proven LN, who had received at least one vaccine dose.
View Article and Find Full Text PDFM1 and M2 Macrophage Polarization Correlates with Activity and Chronicity Indices in Lupus Nephritis.
Life (Basel)
January 2025
Department of Anatomical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, 681 Samsen Road, Dusit, Bangkok 10300, Thailand.
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), characterized by inflammation and immune dysregulation in the kidneys. The role of macrophage polarization in LN progression remains underexplored. This study examined the association between tubulointerstitial M1/M2 macrophage subpopulations and LN indices of activity and chronicity.
View Article and Find Full Text PDFIdentifying potential mechanism and targets for treatment of tertiary lymphoid structure in lupus nephritis based on bioinformatics analysis.
Int Immunopharmacol
January 2025
Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. Electronic address:
Background: Tertiary lymphoid structure (TLS) is an ectopic lymphoid structure that develops in non-lymphoid structures. Some studies have shown that the TLS formed in autoimmune diseases, such as lupus nephropathy (LN), can cause damage to normal tissues and continuous disease progression. Nevertheless, there is still a lack of efficient treatments for TLS in LN.
View Article and Find Full Text PDFDeveloping a Label-Free Infrared Spectroscopic Analysis with Chemometrics and Computational Enhancement for Assessing Lupus Nephritis Activity.
Biosensors (Basel)
January 2025
National Synchrotron Radiation Research Center, Hsinchu 300092, Taiwan.
Patterns of disease and therapeutic responses vary widely among patients with autoimmune glomerulonephritis. This study introduces groundbreaking personalized infrared (IR)-based diagnostics for real-time monitoring of disease status and treatment responses in lupus nephritis (LN). We have established a relative absorption difference (RAD) equation to assess characteristic spectral indices based on the temporal peak heights (PHs) of two characteristic serum absorption bands: ν as the target signal and ν as the PH reference for the ν absorption band, measured at each dehydration time (t) during dehydration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!